STRONGTROPIN 100iu*10 x 10UI vials.
STRONGTROPIN is a kind of sterile, lyophilized formulation of Recombinant Human Growth Hormone (HGH) with 191 amino acids, derived from engineering E.coli, and it is identical to the natural growth hormone in amino acid sequence and three-dimension structure. STRONGTROPIN® is indicated for growth failure due to endogenous growth hormone deficiency (GHD) and Turner disease or Kidney failure. STRONGTROPIN® can be used to heal up the surgery wound or burned wound and it has good effect to preservation for human aging.
STRONGTROPIN exerts the same actions of endogenous human growth hormone (HGH). It can stimulate proliferation and differentiation of epiphysis chondrocyte, stimulate growth of cartilage matrix cells, stimulate proliferation and differentiation of osteoblast; thus accelerate the liner growth rate and improve epiphysis width. STRONGTROPIN® can promote protein synthesis in whole body; reverse the negative nitrogen equilibrium caused by wound and surgery; correct the hypoproteinemia due to severe infection or hepatocirrhosis; stimulate synthesis of immune globin and proliferation of lymphadenoid, macrophage and lymphocyte, thus enhance the ability of infection resistance; stimulate proliferation of collagenocyte, fibroblast and macrophage in sites of burn and surgery, thus accelerate wound healing; promote synthesis of cardiocytes, thus improve cardiac contractility and reduce cardiac oxygen consumption; regulate lipometabolism, thus depress serum cholesterol and low density lipoprotein level; complement insufficiency or deficiency of growth hormone, regulate adult lipometabolism, osteometabolism, heart and kidney function.
When reconstitution 1 ml sterile water for injection should be injected along the bottle wall, then swirl the vial with gentle rotary motion until the contents are completely dissolved, do not shake violently.
The recommended dosage of STRONGTROPIN for the treatment of children growth failure is 0.1~0.15IU/kg daily subcutaneous administration for 3 months to 3 years. Therapy regimen could be modified according to experienced doctors’ suggestion.
The recommended dosage of STRONGTROPIN for the treatment of severe burn is 0.2~0.14IU/kg daily subcutaneous administration for 2 weeks.
Side effects :
Growth hormone may cause transient hyperglycemia; it can be recovered as the administration proceeded or terminated.
Adverse reactions occurred in about 1% short stature children in clinical trial. Common adverse reactions include slight pain, tingle, turgescence around the injection site and peripheral edema, arthralgias. All of those adverse reactions often occurred at the beginning of treatment, and were temporal and tolerable. Long-term and high dosage administration of rhGH may develop the antibodies in a few patients. However, the antibodies concentration could be rarely up to as high as 2 mg/L that might affect the therapeutic efficiency.
1. STRONGTROPIN should not be used in patients whose epiphysis had been closed.
2. STRONGTROPIN should not be used in cancer patients with active neoplasia. GH therapy should be discontinued if evidence of neoplasia develops.
3. STRONGTROPIN should not be used in patients in acute shock stage with severe infection.
[WARNINGS AND PRECAUTIONS]
1. rhGH therapy should be conducted on exactly diagnosed GHD patients under advice of experienced doctor.
2. For diabetes patients, dosage of anti-glucourea drugs should be adjusted during rhGH thera